ResistanceBio
ClosedMenlo Park, United States · Founded 2016 · $12.8M raised
- Headquarters
- Menlo Park
- Employees
- 11–50
- Founded
- 2016
- Website
- resistance.bio
- Total Funding
- $12.8M
- Last Round
- $12.8M SeedJan 2024
- Rounds
- 1
About
ResistanceBio built ResCu, a cell culture system that mimics the size and diversity of human tumors to model how cancer responds to treatment before drug resistance develops. The platform helps pharmaceutical and biotech partners discover and overcome clinical treatment resistance pre-clinically, targeting a mechanism responsible for roughly 90% of cancer mortality. Co-founded by Nicholas Goldner and Chris Bulow, the company emerged from Y Combinator's Winter 2019 batch and is headquartered in Menlo Park, California.
Summary
ResistanceBio is a Drug Discovery company based in Menlo Park, United States, founded in 2016. It has raised $12.8M in total across 1 round, most recently a $12.8M Seed round in Jan 2024. Investors include Alumni Ventures, Cherubic Ventures and NFX.
Funding History
Jan 2024
Investors
Similar Companies
The nation's first company to integrate specialty pharmacies into hospitals and health systems, h...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/resistancebio"><img src="https://indexed.vc/api/badge/company/resistancebio" alt="ResistanceBio on Indexed.vc" width="260" height="76" /></a>